Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2− Advanced Breast Cancer Enrolled in an Expanded Access Program
Adam Brufsky(University of Pittsburgh), Vered Stearns(Johns Hopkins University), Keith L. Davis(RTI Health Solutions), Debanjali Mitra(Pfizer (United States)), Matthew J. Cotter(Pfizer (United States)), Saurabh Nagar(RTI Health Solutions), Lynn McRoy(Pfizer (United States))
Cited by 20
Related Papers
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
|Journal of Clinical Oncology|2010|800
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
|Journal of Clinical Oncology|2014|795
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751